Small Molecule Ligands Define a Binding Site on the Immune Regulatory Protein B7.1*

The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. To this end, specific small molecule inhibitors of human B7.1 were identified and characterized. These compounds inhibit the binding of B7.1 to both CD28 and CTLA4. Both classes of compounds appear to bind the same site, a relatively small portion of the GFCC′C" face of the N-terminal V-set domain of human B7.1, not present in the homologous B7.2 or even mouse B7.1. This site may represent a rare hot spot for small molecule antagonist design of inhibitors of cell-cell interactions, whose ligands may yield leads for the development of novel immunomodulatory medicines.

[1]  V. Kuchroo,et al.  CD28/B7 costimulation: a review. , 1998, Critical reviews in immunology.

[2]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[3]  M. Beinborn,et al.  A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. , 2001, The Journal of biological chemistry.

[4]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[5]  P. Linsley,et al.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.

[6]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[7]  P. Reilly,et al.  Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. , 1999, Journal of immunology.

[8]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[9]  Michael Loran Dustin,et al.  Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. , 2000, Seminars in immunology.

[10]  R. Willette,et al.  Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor) , 2000 .

[11]  C. Chothia,et al.  The structure of protein-protein recognition sites. , 1990, The Journal of biological chemistry.

[12]  Y. Xiang,et al.  Identification and structural determination of a potent P-selectin inhibitor. , 2001, Bioorganic & Medicinal Chemistry.

[13]  R. B. Pepinsky,et al.  Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses , 1999 .

[14]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[15]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[16]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[18]  D. Slee,et al.  Development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with antiinflammatory activity. , 2001, Journal of medicinal chemistry.

[19]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[20]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[21]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[22]  P. Linsley,et al.  CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics , 1997, The Journal of experimental medicine.

[23]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[24]  Karen N. Allen,et al.  An Experimental Approach to Mapping the Binding Surfaces of Crystalline Proteins , 1996 .

[25]  M. Lawrence,et al.  Shape complementarity at protein/protein interfaces. , 1993, Journal of molecular biology.

[26]  M. Hurle,et al.  Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4 , 1995, The Journal of experimental medicine.

[27]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Whitty,et al.  Multiple Activation States of Integrin α4β1 Detected through Their Different Affinities for a Small Molecule Ligand* , 1999, The Journal of Biological Chemistry.

[29]  M. Lebwohl,et al.  Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte–Associated Antigen 4–Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells , 2000, The Journal of experimental medicine.

[30]  J. Gribben,et al.  Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.

[31]  D. Ringe,et al.  Analysis of the binding surfaces of proteins , 1999, Medicinal research reviews.

[32]  D I Stuart,et al.  Structure and dimerization of a soluble form of B7-1. , 2000, Immunity.

[33]  Yan Zhang,et al.  Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses , 2001, Nature.

[34]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.